𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study

✍ Scribed by Valldeoriola, Francesc; Puig-Junoy, Jaume; Puig-Peiró, Ruth

Book ID
118156231
Publisher
Informa plc
Year
2012
Tongue
English
Weight
251 KB
Volume
16
Category
Article
ISSN
1369-6998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sumanirole versus placebo or ropinirole
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease
✍ Paolo Barone; Janice Lamb; Amanda Ellis; Zoe Clarke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib

Oral solution of levodopa ethylester for
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease
✍ Ruth Djaldetti; Rivkah Inzelberg; Nir Giladi; Amos D. Korczyn; Yehudit Peretz-Ah 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral